UK: Essential Pharma announces €900m recapitalisation
Essential Pharma, a UK-based international specialty pharma group, has completed a €900m (US$945m) financing, through a €600m Gyrus Capital single-asset Continuation Vehicle led by...
Finland: Faron Pharmaceuticals raises funds to complete Phase II of BEXMAB clinical trial
Faron Pharmaceuticals, a clinical-stage biopharmaceutical company, has issued a total of 30,709,056 new shares, corresponding to approximately 29.9% of the company's shares and votes after the...
UK: Pheon completes US$120m Series B to fund ADC pipeline development
Pheon Therapeutics, an Antibody-Drug Conjugate (ADC) specialist developing next generation ADCs for a wide range of hard-to-treat cancers, has completed a US$120m Series B...
Germany: Exyte acquires TTP Group to accelerate growth of biopharma and life sciences business
Exyte, a Germany-based company operating in in the design, engineering, and delivery of high-tech facilities, intends to acquire TTP Group, an engineering firm specializing...
UK: Aspire Pharma strengthens specialty pharma offering with acquisition of Cenoté Pharma
Aspire Pharma, a specialty generics business, has supplemented its organic growth with the acquisition of Cenoté Pharma, a category specialist in carnitine deficiencies.
Financial terms...
France: SERB Pharmaceuticals appoints Wolfeler as its new CEO
SERB Pharmaceuticals, a global specialty pharmaceutical company, has appointed Vanessa Wolfeler as its new CEO effective June 3, 2024. As part of a long-planned...
Netherlands: Fabrice Chouraqui lined up as new CEO at Pharming
Pharming Group, a Netherlands-based developer of protein replacement therapies and precision medicines, has announced that the board has nominated Fabrice Chouraqui to become Pharming’s...
UK: Kent-Athlone Pharma Group appoints Olga Lund as CFO
Kent-Athlone Pharma Group, a UK-based specialty European pharmaceuticals company, has appointed Olga Lund as CFO.
Lund brings over 20 years of experience in the pharmaceuticals industry, following an...
France: SERB Pharma acquiring Y-mAbs Therapeutics for US$412m
France-based SERB Pharmaceuticals, a global specialty pharmaceutical company focused on medicines for rare diseases and medical emergencies, is acquiring Nasdaq-listed Y-mAbs Therapeutics, a US-based...
France: Sanofi adding to neurology pipeline with acquisition of Vigil Neuroscience
Euronext and Nasdaq-listed global healthcare company, Sanofi, has entered into an agreement to acquire US-listed Vigil Neuroscience, a publicly traded clinical-stage biotechnology company focused...
Advertisement
